España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Lexaria Bioscience
LEXXW
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.630000
-0.12
-15.82%
At close: -
$0.800000
0.17
26.98%
After Hours: Oct 22, 9:29 AM EDT
Get Report
Comment
Lexaria Bioscience (LEXXW) Forecast
News
Earnings
Lexaria Bioscience (LEXXW) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Lexaria Bioscience (NASDAQ:LEXXW) Stock
Lexaria Bioscience Stock (NASDAQ: LEXXW)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, October 22, 2024
Lexaria Bioscience Announces That It Has Rece...
Benzinga Newsdesk
Tuesday, October 01, 2024
Lexaria Appoints Michael Shankman As Chief Fi...
Benzinga Newsdesk
Friday, September 27, 2024
Lexaria Receives Independent Review Board App...
Benzinga Newsdesk
Thursday, August 29, 2024
Lexaria Bioscience Announces Tolerability And...
Benzinga Newsdesk
Tuesday, July 16, 2024
Lexaria Preparing For Strategic Growth, Expan...
Benzinga Newsdesk
Monday, July 08, 2024
Lexaria Receives 3 New Patents For Antiviral ...
Benzinga Newsdesk
Thursday, May 23, 2024
Lexaria Awards Contract To A CRO To Perform T...
Benzinga Newsdesk
Monday, May 06, 2024
Lexaria Announces New Research Program To Eva...
Benzinga Newsdesk
Tuesday, April 30, 2024
Lexaria To Receive $4.7M Gross Proceeds In Wa...
Benzinga Newsdesk
Tuesday, April 16, 2024
Lexaria Receives Ethics Review Board Approval...
Benzinga Newsdesk
Thursday, March 14, 2024
Lexaria Appoints Nelson Cabatuan As Chief Fin...
Benzinga Newsdesk
Tuesday, March 05, 2024
Lexaria To Begin Diabetes And Weight Loss Ani...
Benzinga Newsdesk
Thursday, December 07, 2023
Lexaria Bioscience Corp. Announces That The C...
Benzinga Newsdesk
Friday, October 13, 2023
Lexaria Enters New Global Exclusive Collaboration And License Agreement With SulfoSyn; Global Exclusivity For All Non-Pharmaceutical Applications Of DehydraTECH-Sulforaphane Has Been Awarded
Happy Mohamed
Thursday, September 21, 2023
Lexaria To Evaluate Impact Of DehydraTECH On ...
Benzinga Newsdesk
Wednesday, August 30, 2023
Lexaria Provides Update On Investigational New Drug Application Progress With The FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Designated As HYPER-H23-1
Happy Mohamed
Wednesday, August 02, 2023
Lexaria's Plans To Study Weight Loss And Diabetes Control In A Human Clinical Study With DehydraTECH-CBD
Happy Mohamed
Friday, July 28, 2023
Lexaria Incorporates New Subsidiary For CPG Products And Updates Human Nicotine Study
Happy Mohamed
Wednesday, July 19, 2023
Lexaria Granted Strategically Important New U.S. Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Happy Mohamed
Friday, June 16, 2023
Lexaria's DehydraTECH-CBD Lowers Blood Glucos...
Benzinga Newsdesk
Tuesday, May 23, 2023
Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases
Vandana Singh
Thursday, May 18, 2023
Lexaria's Hormone Study Shows Significant Enhancement In Oral Estradiol Delivery
Happy Mohamed
Monday, April 24, 2023
Lexaria Awards CRO Contract For Upcoming U.S. Phase 1b Hypertension Study
Happy Mohamed
Thursday, March 02, 2023
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels
Vuk Zdinjak
Monday, January 23, 2023
Former President Of GW Pharmaceuticals USA Jo...
Benzinga Newsdesk
Wednesday, December 21, 2022
Lexaria's DehydraTECH-CBD Achieves Superior H...
Benzinga Newsdesk
Tuesday, December 20, 2022
Lexaria's Human Oral Nicotine Study Begins Do...
Benzinga Newsdesk
Tuesday, November 08, 2022
Lexaria Starts Study Evaluating The Effect Of...
Benzinga Newsdesk
Thursday, October 27, 2022
Lexaria's Human Clinical HYPER-H21-4 Study
Benzinga Newsdesk
Wednesday, July 27, 2022
Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events
Vuk Zdinjak
Tuesday, July 26, 2022
Lexaria's Licensee Premier Wellness Science C...
Benzinga Newsdesk
Tuesday, June 21, 2022
Lexaria Signs Manufacturing And License Agreements With BevNology
Bill Haddad
Wednesday, June 08, 2022
Lexaria Grants License To AnodGen Bioceuticals
Bill Haddad
Monday, June 06, 2022
Lexaria Files Pre-IND Meeting Request Letter ...
Benzinga Newsdesk
Friday, April 22, 2022
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
InvestorBrandNetwork
-
Sponsored
Wednesday, April 20, 2022
Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
InvestorBrandNetwork
-
Sponsored
Tuesday, April 19, 2022
Lexaria Commences Multi-Week Human Clinical H...
Benzinga Newsdesk
Wednesday, April 13, 2022
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
InvestorBrandNetwork
-
Sponsored
Wednesday, March 16, 2022
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
InvestorBrandNetwork
-
Sponsored
Tuesday, March 15, 2022
Lexaria Bioscience Reports First Phase Of Its...
Benzinga Newsdesk
Tuesday, March 08, 2022
Lexaria Granted Important New Oral Nicotine P...
Benzinga Newsdesk
Wednesday, February 02, 2022
Lexaria Highlights Findings In Sildenafil Ani...
Benzinga Newsdesk
Wednesday, December 08, 2021
From Benzinga's Global Small Cap Conference: ...
Benzinga Newsdesk
Lexaria Issues Follow-U Results From Clinical Study Showing DehydraTECHTM-CBD Reduces Arterial Stiffness
Bill Haddad
Wednesday, November 10, 2021
Lexaria 2022 R&D Programs To Include Investig...
Benzinga Newsdesk
Wednesday, November 03, 2021
Lexaria Shares Move Higher; Co Announces New ...
Benzinga Newsdesk
Monday, November 01, 2021
Lexaria Bioscience Reports R&D Program To Com...
Benzinga Newsdesk
Wednesday, October 13, 2021
Lexaria Bioscience Reports Recent Oral THC Ab...
Benzinga Newsdesk
Wednesday, September 08, 2021
Lexaria Begins Investigational New Drug Enabl...
Benzinga Newsdesk
Tuesday, September 07, 2021
Lexaria Bioscience Announces Initial Results From Human Clinical Study Of DehydraTECHTM; Study Evidences Up To 23% Decrease In Blood Pressure With DehydraTECH-CBD Relative to Placebo
Bill Haddad
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch